Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7058622 | 1.00 | MEN1 (0.54) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL9643788 | 0.81 | LMNA (0.60) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL4083554 | 0.81 | LMNA (0.60) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL7475308 | 0.76 | ALDH1A1 (0.70) | ALDH1A1GAAMAPK1CYP2C19PKM | |
| SCHEMBL7054422 | 0.76 | ALDH1A1 (0.60) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL6156980 | 0.76 | CTBP2 (0.61) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL7054419 | 0.76 | ALDH1A1 (0.60) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL6156975 | 0.76 | CTBP2 (0.61) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL6156969 | 0.76 | CTBP2 (0.61) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL7056247 | 0.75 | ALDH1A1 (0.65) | MEN1KMT2ALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608196-B2 | Structurally diverse; parallel approach | GALILEO PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20030100750-A1 | Process for solid supported synthesis of pyruvate-derived compounds | EDISON PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100750-A1 | Process for solid supported synthesis of pyruvate-derived compounds | PC, PDK4, PDK1 | MEN1 2070/4885KMT2A 1621/4885LMNA 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.